Development of a novel glutathione repleting agent, L-2-oxothiazolidine-4-carboxylic acid (Procysteine®)

This publication has 54 references indexed in Scilit:

• Imbalance between oxidants and antioxidants in the lungs of HIV-seropositive individuals
  Chemico-Biological Interactions, 1994
• Toxicity evaluations of l-cysteine and Procysteine™, a cysteine prodrug, given once intravenously to neonatal rats
  Toxicology Letters, 1993
• CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses
  International Immunology, 1991
• Clinical Pharmacokinetics of N-Acetylcysteine
  Clinical Pharmacokinetics, 1991
• Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester.
  Proceedings of the National Academy of Sciences, 1989
• Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide
  Cancer, 1988
• Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine
  European Journal of Clinical Pharmacology, 1988
• OXIDANT ACTIVITY IN EXPIRED BREATH OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROME
  The Lancet, 1986
• Changes in the cardiac glutathione status after ischemia and reperfusion
  Cellular and Molecular Life Sciences, 1985
• The Treatment of Acetaminophen Poisoning
  Annual Review of Pharmacology and Toxicology, 1983